Investigational Drug Information for CRLX101
✉ Email this page to a colleague
What is the drug development status for CRLX101?
CRLX101 is an investigational drug.
There have been 12 clinical trials for CRLX101.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2012.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, and Carcinoma, Renal Cell. The leading clinical trial sponsors are Cerulean Pharma Inc., NewLink Genetics Corporation, and National Cancer Institute (NCI).
There are fifty-one US patents protecting this investigational drug and five hundred and fifty-one international patents.
Summary for CRLX101
| US Patents | 51 |
| International Patents | 551 |
| US Patent Applications | 154 |
| WIPO Patent Applications | 112 |
| Japanese Patent Applications | 78 |
| Clinical Trial Progress | Phase 2 (2012-11-01) |
| Vendors | 13 |
Recent Clinical Trials for CRLX101
| Title | Sponsor | Phase |
|---|---|---|
| Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment | National Cancer Institute (NCI) | Phase 2 |
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors | Cerulean Pharma Inc. | Phase 1 |
Clinical Trial Summary for CRLX101
Top disease conditions for CRLX101
Top clinical trial sponsors for CRLX101
US Patents for CRLX101
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CRLX101 | See Plans and Pricing | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (Brentford, Middlesex, GB) | See Plans and Pricing |
| CRLX101 | See Plans and Pricing | Benzimidazole derivatives as PI3 kinase inhibitors | GlaxoSmithKline LLC (Wilmington, DE) | See Plans and Pricing |
| CRLX101 | See Plans and Pricing | ICOS binding proteins | GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB) | See Plans and Pricing |
| CRLX101 | See Plans and Pricing | Benzimidazole derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (Wilmington, DE) | See Plans and Pricing |
| CRLX101 | See Plans and Pricing | Cancer treatment method | SmithKline Beecham (Cork) Limited (Carrigaline, IE) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CRLX101
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CRLX101 | Australia | AU2012236868 | 2031-03-25 | See Plans and Pricing |
| CRLX101 | Brazil | BR112013024502 | 2031-03-25 | See Plans and Pricing |
| CRLX101 | Canada | CA2831143 | 2031-03-25 | See Plans and Pricing |
| CRLX101 | Chile | CL2013002737 | 2031-03-25 | See Plans and Pricing |
| CRLX101 | China | CN103857393 | 2031-03-25 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
